Fabrazyme
Payments companies reported to CMS as associated with Fabrazyme. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Fabrazyme, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Fabrazyme
These are the largest totals companies reported as associated with Fabrazyme. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Ankit Mehta | Dallas, TX | Nephrology (Internal Medicine) | $319,878.64 |
| Maryam Banikazemi | Valhalla, NY | $242,171.40 | |
| Joseph Ray | Galveston, TX | Clinical Genetics (M.D.) | $170,304.88 |
| Anjay Rastogi | Los Angeles, CA | Nephrology (Internal Medicine) | $121,041.78 |
| Michael Lipinski | Fort Myers, FL | Cardiovascular Disease | $109,441.13 |
| Kristin Scott-Tillery | Billings, MT | Advanced Heart Failure and Transplant Cardiology | $108,813.31 |
| Robert Hopkin | Cincinnati, OH | Clinical Genetics (M.D.) | $102,834.46 |
| Linda Spencer | Troy, MI | Nurse Practitioner | $97,575.57 |
| Tariq Shah | Los Angeles, CA | Nephrology (Internal Medicine) | $85,790.10 |
| Richard Rogers | Greenville, SC | Clinical Genetics (M.D.) | $81,734.94 |
Prescribed Fabrazyme?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.